Can a peptide supplement tame blood sugar spikes?

NCT ID NCT07711288

Not yet recruiting Disease control Sponsor: Lembas Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This two-part study investigates Lembas Edge, a dietary supplement derived from a peptide. Part 1 tests its safety and tolerability in healthy adults. Part 2 evaluates its ability to control blood sugar after meals in overweight or obese adults with prediabetes. Participants take the supplement or a placebo before a meal, and researchers measure blood sugar and insulin responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alpha-galactosidase-derived peptide (Lembas Edge)
What this could lead to: If successful, this supplement could offer a new way to help manage blood sugar spikes after meals in people with prediabetes.
What could go wrong: This is an early, small study. The supplement may not prove effective, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPRANDIAL GLYCEMIC CONTROL PREDIABETIC OVERWEIGHT AND OBESE ADULTS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

KGK Science Inc.

London, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.